Novavax Inc
NVAX
View Detailed Chart
9.335USD
-0.385-3.96%
Market hours （ET）Quotes delayed by 15 min
57.00MMarket Cap
3.43P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.96%
5 Days
-12.27%
1 Month
-1.32%
6 Months
+8.04%
Year to Date
+38.91%
1 Year
+21.39%
View Detailed Chart
TradingKey Stock Score of Novavax Inc
Currency: USD Updated: 2026-03-24Key Insights
Novavax Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 77 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 13.12.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Novavax Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Novavax Inc Highlights
StrengthsRisks
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 3.41, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 103.32M shares, decreasing 4.45% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 175.80K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.03.
Analyst Rating
Based on
9
analysts
Hold
Current Rating
13.125
Target Price
+36.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Novavax Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Novavax Inc Info
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Ticker SymbolNVAX
CompanyNovavax Inc
CEOJacobs (John C)
Websitehttps://www.novavax.com/?locale=US
Related Instruments
+1.38%
+0.10%
+1.92%
+0.68%
+2.57%
+0.49%
+1.79%
+1.59%
+0.28%
+1.32%
-1.52%
+5.34%
+2.06%
+2.88%
+0.86%
0.00%
+1.94%
+1.86%
+1.19%
+2.44%Popular Symbols
252.400
+0.760 (+0.30%)
178.730
+3.530 (+2.01%)
70651.990
+588.800 (+0.84%)
296.625
+1.835 (+0.62%)
2162.950
+16.970 (+0.79%)
385.960
+2.930 (+0.77%)
4525.300
+54.800 (+1.23%)
90.849
+2.746 (+3.12%)
1.156
-0.005 (-0.40%)
159.478
+0.783 (+0.49%)
